| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Meranzin targets α2-adrenergic receptors. It modulates these receptors and participates in AMPA-ERK1/2-BDNF signaling. By modulating α2-adrenergic receptors, it influences noradrenergic signaling pathways. The compound's involvement in AMPA-ERK1/2-BDNF signaling suggests it may also modulate glutamatergic and neurotrophic pathways. Its anti-inflammatory and analgesic properties are mediated through these signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, Meranzin demonstrates anti-inflammatory and analgesic properties. It modulates α2-adrenergic receptors and participates in AMPA-ERK1/2-BDNF signaling. The compound's activity is typically assessed by measuring its effects on inflammatory cytokine production, receptor binding, and signaling pathway activation. Standard in vitro assays include receptor binding studies, ELISA-based cytokine measurements, and Western blot analysis of signaling proteins.
|
| ln Vivo |
In vivo, Meranzin may be used to prevent the comorbidities of atherosclerosis and depression due to its significant anti-inflammatory and analgesic properties. It is extracted from purple jasmine leaves and has been studied for its potential in preventing atherosclerosis and depression comorbidities. However, comprehensive in vivo efficacy data from published literature are limited. The compound is primarily used as a research tool.
|
| Enzyme Assay |
For non-cell-based receptor binding assays, Meranzin can be evaluated using membrane preparations from tissues or cells expressing α2-adrenergic receptors. Radioligand binding displacement experiments are performed using a suitable radiolabeled ligand such as [3H]-RX821002 or [3H]-yohimbine. Membrane homogenates are incubated with increasing concentrations of the test compound and a fixed concentration of the radioligand at room temperature for 60-90 minutes. Bound radioligand is separated from free by rapid filtration through glass fiber filters. Non-specific binding is determined in the presence of excess unlabeled yohimbine. IC50 values are calculated from displacement curves.
|
| Cell Assay |
For in vitro cellular assays, cells expressing α2-adrenergic receptors or neuronal cells are cultured in appropriate media. For functional assays, the inhibition of forskolin-stimulated cAMP accumulation is measured. Cells are treated with various concentrations of Meranzin in the presence of an α2-agonist. cAMP levels are measured using ELISA or HTRF-based detection. For anti-inflammatory assays, immune cells are stimulated with LPS or other inflammatory stimuli in the presence or absence of the compound, and cytokine production is measured.
|
| Animal Protocol |
For in vivo animal studies, Meranzin can be administered to rodents via oral gavage. In models of atherosclerosis, vascular plaque formation and inflammatory markers are assessed following compound administration. In models of depression, behavioral tests such as the forced swim test or tail suspension test are performed. Dosing regimens vary depending on the specific model and desired exposure levels. Blood and tissue samples may be collected for pharmacokinetic analysis.
|
| ADME/Pharmacokinetics |
Meranzin has a molecular weight of 260.29 and a molecular formula of C15H16O4. It is a bioactive coumarin compound derived from Traditional Chinese Medicine and isolated from Murraya exotica L. leaves. The compound is supplied with a purity of ≥98%. It is for research use only and is not intended for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Meranzin has not been extensively reported. As a naturally occurring coumarin with anti-inflammatory properties, it is expected to have a favorable safety profile. The compound is for research use only and is not intended for human consumption. Standard toxicological evaluation would include acute and repeated-dose toxicity studies.
|
| References |
|
| Additional Infomation |
Merazine has been reported to be found in Syzygium fragilis, Ferula sovitae, and other organisms for which data is available.
Meranzin (hesperitone, CAS 23971-42-8) is a bioactive coumarin compound derived from Traditional Chinese Medicine and isolated from Murraya exotica L. leaves. It modulates α2-adrenergic receptors and participates in AMPA-ERK1/2-BDNF signaling. It has significant anti-inflammatory and analgesic properties and may be used to prevent the comorbidities of atherosclerosis and depression. It is available for research purposes only. |
| Molecular Formula |
C15H16O4
|
|---|---|
| Molecular Weight |
260.29
|
| Exact Mass |
260.104
|
| CAS # |
23971-42-8
|
| PubChem CID |
1803558
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
414.8±45.0 °C at 760 mmHg
|
| Flash Point |
185.3±28.8 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.567
|
| LogP |
1.92
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
19
|
| Complexity |
401
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC1([C@@H](O1)CC2=C(C=CC3=C2OC(=O)C=C3)OC)C
|
| InChi Key |
LSZONYLDFHGRDP-LBPRGKRZSA-N
|
| InChi Code |
InChI=1S/C15H16O4/c1-15(2)12(19-15)8-10-11(17-3)6-4-9-5-7-13(16)18-14(9)10/h4-7,12H,8H2,1-3H3/t12-/m0/s1
|
| Chemical Name |
8-[[(2S)-3,3-dimethyloxiran-2-yl]methyl]-7-methoxychromen-2-one
|
| Synonyms |
Meranzin; 23971-42-8; 8-[[(2S)-3,3-dimethyloxiran-2-yl]methyl]-7-methoxychromen-2-one; 8-(((2S)-3,3-dimethyloxiran-2-yl)methyl)-7-methoxychromen-2-one; RefChem:156545;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (384.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8419 mL | 19.2093 mL | 38.4187 mL | |
| 5 mM | 0.7684 mL | 3.8419 mL | 7.6837 mL | |
| 10 mM | 0.3842 mL | 1.9209 mL | 3.8419 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
